LENZ Therapeutics, Inc. (LENZ)

Market Cap	706.20M
Revenue (ttm)	n/a
Net Income (ttm)	-49.77M
Shares Out	27.54M
EPS (ttm)	-2.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	145,486
Open	26.35
Previous Close	26.53
Day's Range	25.44 - 27.78
52-Week Range	14.42 - 38.93
Beta	n/a
Analysts	Strong Buy
Price Target	38.00 (+48.21%)
Earnings Date	Mar 19, 2025

About LENZ

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021.The company was founded in 2013 and is headquartered in Solana Beach, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: LENZ
• Website: https://www.lenz-tx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 6 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price forecast is $38.0, which is an increase of 48.21% from the latest price.

Price Target

$38.0

(48.21% upside)

Analyst Consensus: Strong Buy